Skip to main content

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) on behalf of Axsome stockholders. Our investigation concerns whether Axsome has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On August 9, 2021, Axsome announced that the FDA had found deficiencies with its New Drug Application (NDA) for AXS-05. The Company said it was attempting to determine the nature of the deficiencies, and that this announcement may delay the approval of AXS-05.

On this news, the price of Axsome shares fell 46.5% on August 9, 2021, to close at $27.37, down from the previous close price of $51.16.

If you purchased or otherwise acquired Axsome shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.